We are committed to participating in as many existing IBD trials as possible to provide the best treatment opportunities for our patients.

Our goal is to contribute to the research that will one day find a cure for IBD, and in the meantime, to help our patients live more fulfilling, symptom-free lives.

 
Active Crohn's clinical trials

Active Crohn's clinical trials

New medical therapies in the IBD pipeline (for patients who have failed steriods, immunomodulators and/or biologic therapy)

ADVANCE

Rizankizumab (anti-IL 23) 

An open label extension study enrolling moderate to severe Crohn’s disease patients that have failed one or more of the following: oral or local steroids; systemic steroids; immunomodulators; and/or biologic therapy 

MOTIVATE

Rizankizumab (anti-IL 23)  

A study enrolling moderate to severe Crohn’s disease patients that have failed one or more biologic therapy

U-Achieve

Upadacitinib (anti-Jak 1) 

A study enrolling moderate to severe ulcerative colitis patients that failed one or more biologic therapy

Early diagnosis/treatment of Crohn's

Explorer

 Vedolizumab IV, Adalimumab SC, and oral Methotrexate  

An open label, triple therapy, phase 4 study for early treatment of Crohn’s disease

For patients with moderate to severe Crohn's or fistulizing Crohn's patients

GALAXI

Guselkumab (anti-IL 23) 

A phase 2/3 study enrolling moderate to severe Crohn’s disease patients or fistulizing Crohn’s disease patients, with past colitis, ileitis, or ileocolitis

Yellowstone

Oral Ozanimod (S1P1 and S1P5 agonist)

Phase 3 study of oral small molecule for moderate to severe active Crohn's disease

Active Ulcerative Colitis clinical trials

Active Ulcerative Colitis clinical trials

Fortify

Rizankizumab (anti-IL 23)  

An open label extension study enrolling moderate to severe Crohn’s disease patients that have failed one or more of the following: oral or local steroids; systemic steroids; immunomodulators; and/or biologic therapy 

Registry Trials

Registry Trials

BIOME

This registry study includes patients with ulcerative colitis and Crohn’s disease. In addition to brief interviews completed over the phone, patients are asked to collect and ship a stool sample four times over an 18-month period. Family and friends of the patients with IBD are also asked to participate.

SBS Registry

A registry collecting data on patients with short bowel syndrome
Other/miscellaneous trials

Other/miscellaneous trials

BLINK

Comparison of capsule endoscopy to ileocolonscopy plus MRE

DINE - Nutrition study

Trial of the effectiveness of a Mediterranean diet versus a specific carbohydrate diet to induce remission of Crohn's disease

SEAVUE

This phase 3B trial is a first-of-its-kind, head-to-head study of the effectiveness of Ustekinumab (Stelara) versus Adalimumab (Humria) in the treatment of severe Crohn’s disease that has not been previously treated with a biologic therapy. There is no placebo in this trial—all patients will receive an active medication.